Cited 10 times in
A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 박준용 | - |
dc.date.accessioned | 2014-12-19T16:28:09Z | - |
dc.date.available | 2014-12-19T16:28:09Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89585 | - |
dc.description.abstract | Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA≥60 IU/ml after ≥6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log10 IU/ml, respectively. A greater proportion of entecavir-switch than lamivudine-maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log10 IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ANTIVIRAL THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antiviral Agents/administration & dosage | - |
dc.subject.MESH | Antiviral Agents/adverse effects | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Drug Resistance, Viral | - |
dc.subject.MESH | Drug Substitution | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Guanine/administration & dosage | - |
dc.subject.MESH | Guanine/adverse effects | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/administration & dosage | - |
dc.subject.MESH | Lamivudine/adverse effects | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Viral Load | - |
dc.subject.MESH | Young Adult | - |
dc.title | A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Jeong Heo | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Heon Ju Lee | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Ki Tae Yoon | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Mong Cho | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.identifier.doi | 10.3851/IMP2277 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00191 | - |
dc.identifier.eissn | 2040-2058 | - |
dc.identifier.pmid | 22872647 | - |
dc.identifier.url | http://www.intmedpress.com/journals/avt/article.cfm?id=2277&pid=88&sType=AVT | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Aged, 80 and over | - |
dc.subject.keyword | Antiviral Agents/administration & dosage | - |
dc.subject.keyword | Antiviral Agents/adverse effects | - |
dc.subject.keyword | Antiviral Agents/therapeutic use* | - |
dc.subject.keyword | Drug Resistance, Viral | - |
dc.subject.keyword | Drug Substitution | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Guanine/administration & dosage | - |
dc.subject.keyword | Guanine/adverse effects | - |
dc.subject.keyword | Guanine/analogs & derivatives* | - |
dc.subject.keyword | Guanine/therapeutic use | - |
dc.subject.keyword | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Lamivudine/administration & dosage | - |
dc.subject.keyword | Lamivudine/adverse effects | - |
dc.subject.keyword | Lamivudine/therapeutic use* | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | ROC Curve | - |
dc.subject.keyword | Treatment Outcome | - |
dc.subject.keyword | Viral Load | - |
dc.subject.keyword | Young Adult | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.citation.volume | 17 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1563 | - |
dc.citation.endPage | 1570 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL THERAPY, Vol.17(8) : 1563-1570, 2012 | - |
dc.identifier.rimsid | 32331 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.